KR20010089904A - p53 모르폴리노-기초 안티센스 - Google Patents
p53 모르폴리노-기초 안티센스 Download PDFInfo
- Publication number
- KR20010089904A KR20010089904A KR1020017005184A KR20017005184A KR20010089904A KR 20010089904 A KR20010089904 A KR 20010089904A KR 1020017005184 A KR1020017005184 A KR 1020017005184A KR 20017005184 A KR20017005184 A KR 20017005184A KR 20010089904 A KR20010089904 A KR 20010089904A
- Authority
- KR
- South Korea
- Prior art keywords
- oligonucleotide
- morpholino
- oligonucleotides
- antisense
- modified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (30)
- 적당한 제약학적 담체중의 5'-TCA GTC TGA GTC AGG CCC-3' 로 확인되는 염기 서열 SEQ ID NO:1, 또는 5'-CCC TGC TCC CCC CTG GCT CC-3' 로 확인되는 염기서열 SEQ ID NO:2 를 가지는 안티센스 약제의 제약학적 유효량을 대상에 투여하는 것을 포함하는 포유 동물 대상에 p53 의 유발을 특징으로하는 질병 상태를 치료하는 방법으로서, 안티센스 약제는 모르폴리노 올리고뉴클레오티드, 펩티드 핵산, 2'-O-알릴 또는 2'-O-알킬 변형된 올리고뉴클레오티드, N3'-P5' 포스포르아미데이트 올리고뉴클레오티드, 또는 C-5-프로핀 피리미딘-변형된 올리고뉴클레오티드인 방법.
- 제 1 항에 있어서, 안티센스 약제는 모르폴리노 올리고뉴클레오티드인 것을 특징으로 하는 방법.
- 제 2 항에 있어서, 모르폴리노 올리고뉴클레오티드는 포스포로디아미데이트 골격 결합에 의해 연결된 모르폴리노 서브유닛을 포함하는 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 올리고뉴클레오티드는 C-5-프로핀 피리미딘-변형된 올리고뉴클레오티드인 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 안티센스 약제는 서열 SEQ ID NO:1 을 가지는 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 안티센스 약제는 서열 SEQ ID NO:2 을 가지는 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 상기 대상은 인간 대상인 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 상기 질병 상태는 암인 것을 특징으로 하는 방법.
- 제 8 항에 있어서, 세포 수준에서 라디칼 산소 종을 증가시키기에 효과적인 약제로 상기 대상의 치료를 더 포함하는 것을 특징으로 하는 방법.
- 제 9 항에 있어서, 상기 약제는 방사선 증감제, 이온화 방사선, 고압 산소 환경, 및 세포 수준에서 라디칼 산소 종을 증가시키는 화학요법제로부터 선택되는 것을 특징으로 하는 방법.
- 제 10 항에 있어서, 상기 화학요법제는 안트라사이클린 또는 안트라퀴논인 것을 특징으로 하는 방법.
- 제 8 항에 있어서, 세포 주기의 G2기로부터 M 기로의 진행 방해에 효과적인 약제에 의한 상기 대상의 치료를 더 포함하는 것을 특징으로 하는 방법.
- 제 12 항에 있어서, 상기 약제는 포스포키나제 C (PKC) 저해제, 비스(클로로에틸)니트로소우레아(BCNU), 펜톡시필린, 실리마린, 스타우로스포린, 페닐아히스틴,파클리탁셀, 레티노산, 플라보피리돌, 메틸-2,5-디히드로신나메이트, 헤르복시디엔, 9-니트로캠프토테신, 마이토톡신, 아피게닌, 노코다졸, 및 콜세미드로 구성된 군으로부터 선택된 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 상기 질병 상태는 국소 빈혈 또는 국소빈혈/재살포 상해로부터 유발되는 것을 특징으로 하는 방법.
- 5'-TCA GTC TGA GTC AGG CCC-3' 으로 확인되는 SEQ ID NO:1, 및 5'-CCC TGC TCC CCC CTG GCT CC-3' 로 확인되는 SEQ ID NO:2 로 구성되는 군으로부터 선택된 염기 서열을 가지는 안티센스 약제, 및 적당한 제약학적 담체를 포함하며, 안티센스 약제는 모르폴리노 올리고뉴클레오티드,펩티드 핵산,2'-O-알릴 또는 2'-O-알킬 변형된 올리고뉴클레오티드, 및 N3'→ P5' 포스포르아미데이트 올리고뉴클레오티드, 또는 C-5-프로핀 피리미딘-변형된 올리고뉴클레오티드인 것을 특징으로 하는 대상에 p53 유발을 특징으로하는 질병 상태 치료에 사용하기 위한 조성물.
- 제 15 항에 있어서, 안티센스 약제는 모르폴리노 올리고뉴클레오티드인 것을 특징으로 하는 조성물.
- 제 16 항에 있어서, 모르폴리노 올리고뉴클레오티드는 포스포로디아미데이트 골격 결합에 의해 연결된 모르폴리노 서브유닛을 포함하는 것을 특징으로 하는 조성물.
- 제 15 항에 있어서, 올리고뉴클레오티드는 C-5-프로핀 피리미딘-변형된 올리고뉴클레오티드인 것을 특징으로 하는 조성물.
- 제 15 항에 있어서, 안티센스 약제는 서열 SEQ ID NO:1 을 가지는 것을 특징으로 하는 조성물.
- 제 15 항에 있어서, 안티센스 약제는 서열 SEQ ID NO:2 를 가지는 것을 특징으로 하는 조성물.
- 5'-TCA GTC TGA GTC AGG CCC-3 으로 확인되는 SEQ ID NO:1, 및 5'-CCC TGC TCC CCC CTG GCT CC-3' 로 확인되는 SEQ ID NO:2 로 구성되는 군으로부터 선택된 염기 서열을 가지는 올리고뉴클레오티드로서, 올리고뉴클레오티드는 모르폴리노 올리고뉴클레오티드, 펩티드 핵산, 2'-O-알릴 또는 2'-O-알킬 변형된 올리고뉴클레오티드, 및 N3'→ P5' 포스포르아미데이트 올리고뉴클레오티드로 구성된 군으로부터 선택되는 올리고뉴클레오티드.
- 제 21 항에 있어서, 염기 서열 SEQ ID NO:1 을 가지는 것을 특징으로 하는 올리고뉴클레오티드.
- 제 21 항에 있어서, 염기 서열 SEQ ID NO:2 를 가지는 것을 특징으로 하는 올리고뉴클레오티드.
- 제 23 항에 있어서, 올리고뉴클레오티드는 모르폴리노 올리고뉴클레오티드인 것을 특징으로 하는 올리고뉴클레오티드.
- 제 24 항에 있어서, 포스포로디아미데이트 골격 결합에 의해 연결된 모르폴리노 서브유닛을 포함하는 것을 특징으로 하는 모르폴리노 올리고뉴클레오티드.
- 제 23 항에 있어서, 올리고뉴클레오티드는 모르폴리노 올리고뉴클레오티드인 것을 특징으로 하는 올리고뉴클레오티드.
- 제 26 항에 있어서, 포스포로디아미데이트 골격 결합에 의해 연결된 모르폴리노 서브유닛을 포함하는 것을 특징으로 하는 모르폴리노 올리고뉴클레오티드.
- 5'-TCA GTC TGA GTC AGG CCC-3' 로 확인되는 SEQ ID NO:1, 및 5'-CCC TGC TCC CCC CTG GCT CC-3' 로 확인되는 SEQ ID NO:2 로 구성되는 군으로부터 선택된 염기 서열을 가지는 올리고뉴클레오티드로서, C-5-프로핀 피리미딘-변형된 올리고뉴클레오티드인 올리고뉴클레오티드.
- 제 28 항에 있어서, 염기서열 SEQ ID NO:1 을 가지는 것을 특징으로 하는 올리고뉴클레오티드.
- 제 28 항에 있어서, 염기서열 SEQ ID NO:2 를 가지는 것을 특징으로 하는 올리고뉴클레오티드.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10569598P | 1998-10-26 | 1998-10-26 | |
US60/105,695 | 1998-10-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010089904A true KR20010089904A (ko) | 2001-10-13 |
KR100675123B1 KR100675123B1 (ko) | 2007-01-29 |
Family
ID=22307291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017005184A KR100675123B1 (ko) | 1998-10-26 | 1999-10-22 | p53 모르폴리노-기초 안티센스 |
Country Status (10)
Country | Link |
---|---|
US (1) | US6365577B1 (ko) |
EP (1) | EP1124950B1 (ko) |
JP (2) | JP4777515B2 (ko) |
KR (1) | KR100675123B1 (ko) |
AT (1) | ATE332969T1 (ko) |
AU (1) | AU771579B2 (ko) |
CA (1) | CA2347905C (ko) |
DE (1) | DE69932346T2 (ko) |
ES (1) | ES2268903T3 (ko) |
WO (1) | WO2000024885A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7246553B2 (en) | 2003-05-07 | 2007-07-24 | Samsung Electronics Co., Ltd. | Bread maker |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6686338B1 (en) | 1996-02-23 | 2004-02-03 | The Board Of Regents Of The University Of Nebraska | Enzyme inhibitors for metabolic redirection |
FR2790005B1 (fr) * | 1999-02-22 | 2004-01-30 | Commissariat Energie Atomique | Procede de fabrication de morpholino-nucleotides, et utilisation de ceux-ci pour l'analyse et le marquage de sequences d'acides nucleiques |
CA2408746C (en) * | 2000-05-17 | 2010-09-21 | Patrick L. Iversen | Antisense phosporodiamidate morpholino oligonucleotide inhibition of cytochrome p450 to modulate drug pharmacokinetics |
DE10048091A1 (de) * | 2000-09-28 | 2002-04-25 | Ernst Bayer | Anwendung chemisch modifizierter Oligodesoxyribonukleotide zur Unterdrückung der Proliferation von humanem Pankreastumor |
US7105134B2 (en) | 2001-03-13 | 2006-09-12 | Pamgene B.V. | Device for holding a substrate |
CA2463641C (en) * | 2001-10-16 | 2013-07-09 | Avi Biopharma, Inc. | Antisense antiviral agent and method for treating ssrna viral infection |
FR2832154B1 (fr) | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
EP1321522A1 (en) * | 2001-12-18 | 2003-06-25 | Universite De Geneve | Promoting cell survival by inhibiting BARD1 apoptotic activity |
HUE051368T2 (hu) | 2002-03-20 | 2021-03-01 | Univ Maryland | Nem szelektív kationcsatorna idegsejtekben és a csatornát blokkoló vegyületek az agyduzzanat kezelésére |
US8980952B2 (en) * | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
EP1371660A1 (en) * | 2002-06-14 | 2003-12-17 | Consejo Superior De Investigaciones Cientificas | Vaccine |
CA2502681A1 (en) * | 2002-10-23 | 2004-05-06 | Exelixis, Inc. | Mbms as modifiers of branching morphogenesis and methods of use |
JP2006507841A (ja) * | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | 機能的siRNAおよび超機能的siRNA |
AU2003225410A1 (en) | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
WO2005013905A2 (en) * | 2003-08-07 | 2005-02-17 | Avi Biopharma, Inc. | SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION |
NO20035682D0 (no) * | 2003-12-18 | 2003-12-18 | Amersham Health As | Optisk avbildning av ösofagkreft og Barretts ösofag |
US20050197310A1 (en) | 2004-01-30 | 2005-09-08 | Orna Mor | Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases |
CA2572509A1 (en) * | 2004-07-01 | 2006-01-19 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
US8361976B2 (en) * | 2004-07-09 | 2013-01-29 | University Of Massachusetts | Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules |
US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
EP2359832A3 (en) * | 2004-09-18 | 2011-11-23 | University of Maryland, Baltimore | Therapeutic agents targeting the NCCA-ATP channel and methods of use thereof |
DE602005024704D1 (de) * | 2004-09-18 | 2010-12-23 | Univ Maryland | Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür |
US8357664B2 (en) | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
EP1937278B1 (en) * | 2005-09-08 | 2012-07-25 | AVI BioPharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
US8524676B2 (en) * | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
WO2007073149A1 (en) * | 2005-12-22 | 2007-06-28 | Keygene N.V. | Alternative nucleotides for improved targeted nucleotide exchange |
US7825099B2 (en) | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
US20080199961A1 (en) * | 2006-08-25 | 2008-08-21 | Avi Biopharma, Inc. | ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS |
EP3103451A1 (en) * | 2007-01-12 | 2016-12-14 | University of Maryland, Baltimore | Targetting ncca-atp channel for organ protection following ischemic episode |
CA2618099C (en) * | 2007-02-09 | 2016-09-20 | University Of Maryland, Baltimore | Antagonists of a non-selective cation channel in neural cells |
WO2009002832A2 (en) * | 2007-06-22 | 2008-12-31 | University Of Maryland, Baltimore | Inhibitors of ncca-atp channels for therapy |
PT2170403E (pt) | 2007-06-27 | 2014-07-17 | Quark Pharmaceuticals Inc | Composições e métodos para inibição da expressão de genes pró-apoptóticos |
CN101360319B (zh) * | 2007-07-30 | 2011-07-20 | 鼎桥通信技术有限公司 | 一种基于业务量的资源预留方法及装置 |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
CA2704049A1 (en) | 2007-10-26 | 2009-04-30 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
KR101944119B1 (ko) | 2009-11-13 | 2019-01-30 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 안티센스 항바이러스 화합물 및 인플루엔자 바이러스 감염을 치료하는 방법 |
US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
CA2862628C (en) | 2012-01-27 | 2021-08-24 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
US8865761B1 (en) | 2012-08-07 | 2014-10-21 | The University Of Notre Dame Du Lac | Regulation of cholesterol homeostasis |
ES2704855T3 (es) | 2012-09-12 | 2019-03-20 | Quark Pharmaceuticals Inc | Moléculas de oligonucleótido de doble cadena para p53 y métodos de uso de las mismas |
US9932578B2 (en) * | 2012-09-12 | 2018-04-03 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to P53 and methods of use thereof |
WO2021030778A1 (en) * | 2019-08-15 | 2021-02-18 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5405938A (en) * | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
CA2177074A1 (en) * | 1993-11-22 | 1995-06-01 | James R. Bischoff | P53-binding polypeptides and polynucleotides encoding same |
US5641754A (en) * | 1994-01-10 | 1997-06-24 | The Board Of Regents Of The University Of Nebraska | Antisense oligonucleotide compositions for selectively killing cancer cells |
US5968909A (en) * | 1995-08-04 | 1999-10-19 | Hybridon, Inc. | Method of modulating gene expression with reduced immunostimulatory response |
-
1999
- 1999-10-22 AT AT99971033T patent/ATE332969T1/de not_active IP Right Cessation
- 1999-10-22 CA CA002347905A patent/CA2347905C/en not_active Expired - Lifetime
- 1999-10-22 ES ES99971033T patent/ES2268903T3/es not_active Expired - Lifetime
- 1999-10-22 AU AU12217/00A patent/AU771579B2/en not_active Expired
- 1999-10-22 US US09/426,804 patent/US6365577B1/en not_active Expired - Lifetime
- 1999-10-22 EP EP99971033A patent/EP1124950B1/en not_active Expired - Lifetime
- 1999-10-22 DE DE69932346T patent/DE69932346T2/de not_active Expired - Lifetime
- 1999-10-22 WO PCT/US1999/024758 patent/WO2000024885A2/en active IP Right Grant
- 1999-10-22 JP JP2000578439A patent/JP4777515B2/ja not_active Expired - Lifetime
- 1999-10-22 KR KR1020017005184A patent/KR100675123B1/ko active IP Right Grant
-
2011
- 2011-01-20 JP JP2011010285A patent/JP2011079865A/ja not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7246553B2 (en) | 2003-05-07 | 2007-07-24 | Samsung Electronics Co., Ltd. | Bread maker |
Also Published As
Publication number | Publication date |
---|---|
DE69932346T2 (de) | 2007-07-05 |
CA2347905A1 (en) | 2000-05-04 |
JP4777515B2 (ja) | 2011-09-21 |
JP2011079865A (ja) | 2011-04-21 |
EP1124950B1 (en) | 2006-07-12 |
KR100675123B1 (ko) | 2007-01-29 |
CA2347905C (en) | 2009-12-15 |
AU771579B2 (en) | 2004-03-25 |
US6365577B1 (en) | 2002-04-02 |
DE69932346D1 (de) | 2006-08-24 |
WO2000024885A3 (en) | 2000-07-20 |
EP1124950A2 (en) | 2001-08-22 |
ES2268903T3 (es) | 2007-03-16 |
ATE332969T1 (de) | 2006-08-15 |
JP2002528464A (ja) | 2002-09-03 |
AU1221700A (en) | 2000-05-15 |
WO2000024885A2 (en) | 2000-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100675123B1 (ko) | p53 모르폴리노-기초 안티센스 | |
US6312900B1 (en) | Antisense oligonucleotide compositions and methods for the modulation of activating protein 1 | |
KR102275504B1 (ko) | 산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함 | |
AU730916B2 (en) | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins | |
EP2850186B1 (en) | Compositions and methods for modulating smn gene family expression | |
JP2011172597A (ja) | スプライス領域アンチセンス組成物および方法 | |
JP2015518712A (ja) | Mecp2発現を調節するための組成物及び方法 | |
EP1876893A2 (en) | Cancer treatment by combined inhibition of proteasome and telomerase activities | |
WO2000059549A1 (en) | Antisense oligonucleotide compositions and methods for the modulation of jnk proteins | |
JP2015523853A (ja) | Atp2a2発現を調節するための組成物及び方法 | |
JP2015518711A (ja) | Bdnf発現を調節するための組成物及び方法 | |
CA2287314A1 (en) | Rnase l activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies | |
HRP20020075A2 (en) | Oligonucleotides for inhibiting the expression of human eg5 | |
JP2022082544A (ja) | 酸性アルファ-グルコシダーゼ遺伝子に関連する疾患を処置するためのアンチセンスオリゴマーおよびそれを用いる方法 | |
DK2898887T3 (en) | Combination of telomerase inhibitor and gemcitabine for the treatment of cancer | |
US6291668B1 (en) | Oligonucleotide derivatives | |
Prins et al. | Antisense of oligonucleotides and the inhibition of oncogene expression | |
AU1533999A (en) | Decreasing cell proliferation by decreasing levels of pp5 | |
WO1998049287A2 (en) | Antisense oligonucleotides specific for thymidylate synthase | |
WO2023147400A1 (en) | Compositions and methods for inhibiting stag1 expression and uses thereof | |
MXPA05013065A (en) | Modulation of survivin expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130109 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140108 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150107 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160111 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170116 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180109 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190110 Year of fee payment: 13 |